ApoE associated with lipid has a reduced capacity to inhibit β-amyloid fibril formation
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Apolipoprotein E (apoE) and the beta-amyloid peptide are both found in the senile plaques associated with Alzheimer's disease. Several studies have recently determined that apoE can prevent beta-amyloid fibril (Abetaf) formation in vitro. In vivo, apoE is normally associated with a lipid source. We show that both recombinant and purified plasma apoE inhibit Abetaf formation in a dose-dependent manner. The three major apoE isoforms were equipotent at inhibiting Abetaf formation. ApoE associated with either cholesterol-containing liposomes or very low density lipoproteins displayed less potent inhibition of Abetaf formation than their unlipidated counterparts. These results indicate that the presence of associated lipids reduce the ability of apoE to inhibit the formation of Abetaf in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Apolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830
Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid
Wisniewski, T., & Frangione, B. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90444-c · Cited by 802
Fibrillogenesis in Alzheimer's disease of amyloid β peptides and apolipoprotein E
Castano, E. M., Prelli, F., Wisniewski, T., Golabek, A., Kumar, R. A., Soto, C., & Frangione, B. (1995) · Biochemical Journal · doi:10.1042/bj3060599 · Cited by 267
Westerlund, J. A., & Weisgraber, K. H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82318-3 · Cited by 164
Cited by
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
“decreased Aβ fibrillogenesis in vitro by interfering with Aβ nucleation (Beffert and Poirier, 1998; Evans et al., 1995; Webster and Rogers, 1996; Wood et al., 1996).”
BackgroundHuman ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
“Perhaps due to differences in experimental conditions, others have reported that apoE isoforms inhibit the process of Ab aggregation (39, 49, 50), making it difficult to interpret whether they differentially modulate Ab accumulation in vivo.”
Alzheimer’s disease pathogenesis and therapeutic interventions
Parihar, M. S., & Hemnani, T. (2004) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2003.12.007 · Cited by 433
A Mathematical Model of the Kinetics of β-Amyloid Fibril Growth from the Denatured State
Pallitto, M. M., & Murphy, R. M. (2001) · Biophysical Journal · doi:10.1016/s0006-3495(01)75831-6 · Cited by 259
Huynh, T.-P. V., Davis, A. A., Ulrich, J. D., & Holtzman, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075481 · Cited by 210
Metadata
- Authors
- Beffert, U., & Poirier, J.
- Venue
- NeuroReport
- Published
- 1998-10
- Volume
- 9
- Issue
- 14
- Pages
- 3321-3323
- ISSN
- 0959-4965 (ISSN-L)
- OpenAlex
- W2048018325
- Cited by
- 41
- References
- 5
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ApoE associated with lipid has a reduced capacity to inhibit β-amyloid fibril formation. https://app.cochat.ai/papers/10.1097/00001756-199810050-00031
- The paper
- Beffert, U., & Poirier, J. (1998). ApoE associated with lipid has a reduced capacity to inhibit β-amyloid fibril formation. NeuroReport. https://doi.org/10.1097/00001756-199810050-00031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.